News

Evaluation results - EIC Pathfinder Open 2023 call – call deadline 7 March 2023

Published on | 2 years ago

Programmes EIC

For the European Innovation Council (EIC) Pathfinder Open 2023 call a number of 783 proposals were evaluated and 53 selected for funding. Among the successful projects are two consortia with a Flemish coordinator.

  • KU Leuven, FASTCOMET - Future Data Storage Using Colloidal Memory Technology
  • KU Leuven, ArTCell - Bottom-up manufacturing of artificial anti-tumor T cells

More info on the EIC Pathfinder scheme, the Pathfinder Open 2023 call statistics and an overview of all funded projects is available in the EIC news article

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1743 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.